Oncogenic KRAS signaling via the ERK–MAPK–AP-1 pathway induces the expression of immunosuppressive cytokines such as TGF-β1 and IL-10, as shown in KRAS-mutant tumor models [100]. Here, KRAS is linked to neoplasm.